The analysis highlights Daraxonrasib as the first targeted therapy approved for metastatic pancreatic cancer, with clinical data showing it cut the risk of death by more than half. While Amgen reported nearly $36.7 billion in revenue and $7.7 billion in net income for FY 2025, Revolution Medicines' innovative potential makes it a more attractive long-term investment despite its current lack of revenue and widening losses.